Company

eFFECTOR Therapeutics, Inc.

Headquarters: San Diego, CA, United States

Employees: 12

CEO: Dr. Stephen T. Worland Ph.D.

NASDAQ: EFTR

Detailed Description

eFFECTOR Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of selective translation regulator inhibitors for the treatment of cancer. Its lead product candidate is Tomivosertib, an oral small-molecule inhibitor of MNK that is in phase 2b clinical trial for the treatment of patients with metastatic non-small cell lung cancer. The company is also developing Zotatifin, a small molecule designed to inhibit eukaryotic initiation factor 4A (eIF4E), which is in phase 2clinical trial to treat patients with solid tumors. It has a collaboration agreement with Pfizer Inc. to develop inhibitors of eIF4E. eFFECTOR Therapeutics, Inc. was founded in 2012 and is headquartered in Solana Beach, California.

Top 1-year algo backtest: +265.99%

$10,000 in October 2023 would now be $36,599 by following this algorithm daily at market close.

Use AI to boost your investing & swing trading, now!

Try Disfold DeepFinance FREE

Stocks & Indices

eFFECTOR Therapeutics, Inc. has the following listings and related stock indices.


Stock: NASDAQ: EFTR wb_incandescent

Stock: FSX: LWK1 wb_incandescent

Details

Headquarters:

11120 Roselle Street

Suite A

San Diego, CA 92121

United States

Phone: 858 925 8215